Ferring expands activities in Argentina
European speciality biopharmaceutical group Ferring Pharmaceuticals has acquired the Argentinean pharmaceutical company Dupomar, immediately doubling its turnover in Argentina.
European speciality biopharmaceutical group Ferring Pharmaceuticals has acquired the Argentinean pharmaceutical company Dupomar, immediately doubling its turnover in Argentina.
Dupomar specialises in women's and children's health, including treatments for urinary infections, osteoporosis/calcium deficit, pain and inflammation management and its products will complement Ferring's therapeutic areas of endocrinology, gastroenterology, gynecology, infertility and urology.
A new business organisation is underway to maximise the synergies between Ferring and Dupomar for the benefit of the combined portfolio. 'With a stronger presence we can establish a dedicated infertility field force, and be in a good position to focus on coverage beyond the urban centres covered by the existing Ferring sales force,' said Michel L Pettigrew, chief operating officer.
In recent years Ferring has expanded beyond its traditional European base and now has operating subsidiaries in more than 40 countries. This acquisition demonstrates its commitment to expanding its presence in both the therapeutic areas and key geographies in which it operates, the company says. Following the acquisition Ferring-Dupomar has more than 130 employees in Argentina.